
Alnylam Pharmaceuticals (ALNY) Stock
Commercial biotech developing approved medicines for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Alnylam Pharmaceuticals in November 2026.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It’s Moving

Alnylam Faces Investor Scrutiny Amid Legal Investigations and Conference Presentation
- Pomerantz LLP announced it is investigating potential claims on behalf of Alnylam investors, signaling heightened regulatory or litigation risk for shareholders.
- The law firm issued alerts on November 12 and November 17, urging affected investors to contact specific representatives for further information.
- Company executives participated in the Jefferies Global Healthcare Conference 2026 transcript release, providing direct commentary amidst the ongoing legal inquiries.

Alnylam Faces Investor Scrutiny Amid Legal Investigations and Conference Presentation
- Pomerantz LLP announced it is investigating potential claims on behalf of Alnylam investors, signaling heightened regulatory or litigation risk for shareholders.
- The law firm issued alerts on November 12 and November 17, urging affected investors to contact specific representatives for further information.
- Company executives participated in the Jefferies Global Healthcare Conference 2026 transcript release, providing direct commentary amidst the ongoing legal inquiries.
Six-Month Growth Performance
When is the next earnings date for ALNYLAM PHARMACEUTICALS INC (ALNY)?
No confirmed upcoming earnings date has been announced for ALNY as of November 16, 2026. Based on the company's historical reporting pattern, which typically follows a quarterly cycle with reports occurring approximately three months after the previous release, the next report is expected in early February 2027. This anticipated filing will likely cover the fourth quarter and full-year results for fiscal year 2026. Investors should monitor official communications for the precise confirmation of this schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alnylam Pharmaceuticals' stock with a target price of $280.78, indicating strong growth potential.
Financial Health
Alnylam Pharmaceuticals is generating strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.